Stockscreener 앱 받기
2.65
0.76%
0.02
시간 외 거래:
2.70
0.05
+1.89%
전일 마감가:
$2.63
열려 있는:
$2.51
하루 거래량:
165.59K
Relative Volume:
0.82
시가총액:
$33.81M
수익:
-
순이익/손실:
$-15.91M
주가수익비율:
-1.8339
EPS:
-1.445
순현금흐름:
$-15.07M
1주 성능:
-7.34%
1개월 성능:
-13.68%
6개월 성능:
-1.85%
1년 성능:
-42.01%
1일 변동 폭
$2.35
$2.74
1주일 범위
$2.35
$2.87
52주 변동 폭
$1.11
$4.75
Lantern Pharma Inc Stock (LTRN) Company Profile
명칭
Lantern Pharma Inc
전화
972-277-1136
주소
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
2.65 | 33.94M | 0 | -15.91M | -15.07M | -1.445 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-07 | 개시 | H.C. Wainwright | Buy |
Lantern Pharma Inc 주식(LTRN)의 최신 뉴스
Form 8K Lantern Pharma Inc For: 14 August By Investing.com - Investing.com Nigeria
Lantern Pharma Reports 46.2% Wider Q2 2026 Loss at -$0.57/Share - AlphaStreet
Lantern Pharma Releases Q2 2026 Financial Results - AlphaStreet
Lantern Pharma (LTRN) Advances AI-Driven Oncology Pipeline Amid Valuation Challenges - GuruFocus
Lantern Q2 2026 slides: operating loss drops 25%, LP-300 data strengthens - Investing.com Canada
Lantern Pharma Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Lantern Pharma posts q2 2026 loss miss as stock slips - Investing.com Nigeria
LTRN: AI-driven clinical pipeline and Open-Medicine AI spin-out drive growth amid reduced expenses - TradingView
LTRN: Open-Medicine AI spinout and clinical advances drove a leaner Q2 with reduced operating loss - TradingView
Lantern Pharma Q2 2026 Earnings Call Transcript - MarketBeat
BRIEF-Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update - Dailyhunt
Lantern Pharma Q2 EPS of $(0.57) misses estimate by 50% - scanx.trade
Lantern Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is Lantern Pharma Inc (LTRN) Facing Increased Losses After Q2 Earnings Miss? GF Score: 34/100 - GuruFocus
Lantern Pharma Forms Open Medicine AI Subsidiary Business - TipRanks
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price - TradingView
Lantern Pharma Inc. Q2 2026: Net income $(7.07M), EPS $(0.57) — 10-Q Summary - TradingView
Lantern Pharma Reports $7.1 Million Q2 Net Loss as LP-184 Trial Clears - quiverquant.com
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits
Lantern Pharma Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Empery Asset Management, LP Acquires 1.3 Million Shares of Lantern Pharma Inc (LTRN) - GuruFocus
LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET - Business Wire
LTRN Price History for Lantern Pharma Stock - Barchart.com
LTRN Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Lantern Pharma (LTRN): Empery Asset Management discloses 9.99% beneficial stake - Stock Titan
Lantern Pharma Spins Off Open-Medicine AI Platform - TipRanks
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - BioSpace
Lantern Pharma (LTRN) Establishes Open-Medicine AI to Expand Mul - GuruFocus
Lantern Pharma establishes Open-Medicine AI to commercialize multi-agent AI co-scientist platform - TradingView
Lantern Pharma spins out AI platform into Open-Medicine AI - Investing.com
Lantern Pharma spins out AI platform into Open-Medicine AI By Investing.com - Investing.com Canada
Lantern Pharma’s bladder cancer trial cleared by EMA - Investing.com Nigeria
Lantern Pharma (LTRN) Gains EMA Approval for Phase 1b/2 Trial in Bladder Cancer - GuruFocus
Two Tumor Markers Will Guide Lantern Pharma's Bladder Cancer Trial - Stock Titan
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer - Business Wire
LTRN|Lantern Pharma Inc|Price:2.890|Chg%:+0.140 - TradingKey
Lantern Pharma Inc (LTRN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lantern Pharma Inc (LTRN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lantern Pharma Inc (LTRN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lantern Pharma Inc (LTRN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Lantern Pharma Inc. Revenue Breakdown – NASDAQ:LTRN - TradingView
LTRN|Lantern Pharma Inc|Price:2.750|Chg%:-0.120 - TradingKey
Lantern Pharma (LTRN) investor Thomas Satterfield discloses 7.6% stake and 975,000 shares - Stock Titan
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers - BioSpace
Lantern Pharma receives patent allowance for LP-184 biomarker test - Investing.com
Lantern Pharma secures US patent for LP-184 biomarker-guided cancer treatment - scanx.trade
LTRN Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in Precision Oncology Pipeline - dars.gov.et
Lantern Pharma (LTRN) Slides 1.37% as Biotech Sector Faces HeadwindsSwing Entry Signals - dars.gov.et
Lantern Pharma Inc (LTRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):